Biomerica Inc
$ 2.07
-2.36%
08 Jun - close price
- Market Cap 6,396,900 USD
- Current Price $ 2.07
- High / Low $ 2.31 / 2.05
- Stock P/E N/A
- Book Value 1.09
- EPS -1.61
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.55 %
- ROE -0.94 %
- 52 Week High 4.60
- 52 Week Low 1.87
About
Biomerica Inc. (Ticker: BMRA) is a forward-thinking biotechnology firm dedicated to developing and manufacturing advanced diagnostic solutions across medical and food industries. The company focuses on proprietary testing methods targeting metabolic diseases, gastrointestinal disorders, and food intolerances, aiming to enhance healthcare outcomes and diagnostics accuracy. By engaging in strategic research collaborations and leveraging innovative technologies, Biomerica is strategically positioned to address significant unmet medical needs while capitalizing on growth opportunities within the dynamic diagnostics market. Its commitment to a patient-centric approach underscores its potential to drive transformative changes in global healthcare diagnostics.
Analyst Target Price
$13.00
Quarterly Earnings
| Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | Nov 2023 | Aug 2023 | May 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-09 | 2026-01-14 | 2025-10-14 | 2025-08-29 | 2025-04-14 | 2025-01-14 | 2024-10-15 | 2024-08-28 | 2024-04-12 | 2024-01-16 | 2023-10-12 | 2023-08-25 |
| Reported EPS | -0.4358 | -0.45 | 0.0008 | -0.73 | -0.0606 | -0.0555 | -0.0782 | -0.0845 | -0.114 | -0.0896 | -0.1065 | -0.11 |
| Estimated EPS | None | 0 | None | 0 | None | None | None | None | None | 0.04 | -0.02 | -0.08 |
| Surprise | 0 | -0.45 | 0 | -0.73 | 0 | 0 | 0 | 0 | 0 | -0.1296 | -0.0865 | -0.03 |
| Surprise Percentage | None% | None% | None% | None% | None% | None% | None% | None% | None% | -324% | -432.5% | -37.5% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BMRA
2026-06-04 21:10:19
Biomerica has agreed to sell a 6% stake in Diagnosis for $500,000 to affiliates of CEO Zackary Irani. Pending Polish approvals, Biomerica issued a secured 12-month note at 8% to hold the funds, which will be forgiven upon closing, except for 60 days of interest. The transaction is expected to close within 30 days, providing Biomerica with liquidity while regulatory approvals are finalized.
2026-06-04 21:10:19
Biomerica, Inc. has entered into an agreement to sell 78,750 shares of Diagnosis S.A., roughly 6% of its outstanding shares, to buyers affiliated with its CEO, Zackary Irani, for $500,000. The transaction involves a secured promissory term note bearing 8% annual interest, maturing in 12 months from May 29, 2026. Upon completion of the share transfer, the principal and interest exceeding 60 days of accrued interest will be forgiven, effectively leaving Biomerica with the purchase price plus approximately two months of interest.
2026-05-30 05:39:17
Biomerica, Inc. has secured a Master Services Agreement with a confidential life sciences company for over $1.75 million to develop proprietary in vitro diagnostic (IVD) assays. This CDMO engagement leverages Biomerica's existing ELISA-based assay development expertise and infrastructure, providing a new revenue stream while its inFoods® IBS technology remains the primary commercial focus. The development work will be performed at Biomerica’s FDA-licensed facility in California by its current team, creating operating leverage with minimal incremental costs.
2026-05-29 07:40:50
Biomerica Inc. has secured a $1.75 million contract under a Master Services Agreement for the development of in vitro diagnostic (IVD) products. Operating as a contract development and manufacturing organization (CDMO), Biomerica will provide comprehensive services including product development, manufacturing, and related support activities. This agreement highlights Biomerica's capabilities in supporting diagnostic companies.
2026-05-29 07:39:17
Biomerica, Inc. announced it has secured a Master Services Agreement with a confidential life sciences company for over $1.75 million to develop proprietary in vitro diagnostic (IVD) assays. This agreement leverages Biomerica's existing ELISA-based assay development expertise and infrastructure, providing a capital-efficient, parallel revenue stream alongside its primary inFoods® IBS program. The development work will be performed at Biomerica's FDA-licensed facility, with revenue recognized upon milestone completion.
2026-05-28 20:09:35
Biomerica, Inc. announced a Master Services Agreement with an undisclosed life sciences company, valued at over $1.75 million, to develop in vitro diagnostic assays. This deal provides significant near-term revenue visibility for Biomerica, which has recently faced a 23.8% revenue decline, and will be executed by its existing research team in Irvine, California. The company also recently received regulatory approval in the UK for its hp+detect diagnostic test and saw its former CFO move to ConsumerDirect Inc.
